Effects of ImmTOR Tolerogenic Nanoparticles on Innate, Humoral and Cellular Responses in AAV Gene Therapy and Models of Liver Inflammation

Time: 9:30 am
day: Post-Conference Discussion Day - Track A


  • ImmTOR nanoparticles encapsulating rapamycin have been shown to mitigate the antibody response to AAV and enable redosing
  • ImmTOR also inhibits hepatic NFkappaB activation, a master regulator of inflammation, in response to high doses of AAV
  • ImmTOR enhances the tolerogenic environment of the liver and is protective in mouse models of liver inflammation